Martha Chekenya, PhD, University of Bergen in Bergen, Norway, discusses the next steps following the Phase I/II clinical trial (NCT03643549) of bortezomib, a proteasome inhibitor targeting the transcription factor NF kappa beta, to sensitize treatment-refractory glioblastoma tumors to temozolomide chemotherapy, multicenter trial. With nine patients remaining, they have identified distinct molecular biomarkers characterizing responders to their phase two trial, particularly in response to the combination with temozolomide. The aim is to launch a Phase III trial to provide level one evidence regarding the importance of these molecular biomarkers in determining treatment response. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.